Search results
Author(s):
Tian-le Li
,
Mao-long Fu
,
Li-hong Wang
,
et al
Added:
9 months ago
Author(s):
Tian-le Li
,
Mao-long Fu
,
Li-hong Wang
,
et al
Added:
8 months ago
Author(s):
Wei Gao
,
Hui Wang
,
Jian-long Wang
,
et al
Added:
2 months ago
Author(s):
Ton Duy Mai
,
Tri Huynh Quang Ho
,
Sy Van Hoang
,
et al
Added:
8 months ago
Author(s):
Ngoc Huy Nguyen
,
Thanh Ngoc Le
,
Hoai Thi Thu Nguyen
,
et al
Added:
6 months ago
Author(s):
Andrew Wang
Added:
2 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Author(s):
Alberto Cordero
,
Carlos G Santos-Gallego
,
Armando Oterino
,
et al
Added:
3 months ago
Author(s):
Jasper J Brugts
Added:
1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,…
View more
Author(s):
Rajiv Agarwal
Added:
3 months ago
EASD 2025 - Simultaneous finerenone and empagliflozin was a safe therapy option in patients with diabetes and chronic kidney disease (CKD).Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) joins us to discuss safety and efficacy findings from a double-blind, randomised, prespecified subanalysis of CONFIDENCE (NCT05254002), investigating simultaneous finerenone and…
View more
Author(s):
Javed Butler
Added:
4 months ago
ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial.Dr JavedButler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection…
View more